|Número de publicación||US5201318 A|
|Tipo de publicación||Concesión|
|Número de solicitud||US 07/772,620|
|Fecha de publicación||13 Abr 1993|
|Fecha de presentación||4 Oct 1991|
|Fecha de prioridad||24 Abr 1989|
|También publicado como||US5345941|
|Número de publicación||07772620, 772620, US 5201318 A, US 5201318A, US-A-5201318, US5201318 A, US5201318A|
|Inventores||Richard P. Rava, Rebecca Richards-Kortum, Michael S. Feld, Joseph J. Baraga|
|Cesionario original||Rava Richard P, Richards Kortum Rebecca, Feld Michael S, Baraga Joseph J|
|Exportar cita||BiBTeX, EndNote, RefMan|
|Citas de patentes (15), Otras citas (4), Citada por (153), Clasificaciones (13), Eventos legales (7)|
|Enlaces externos: USPTO, Cesión de USPTO, Espacenet|
This is a continuation of co-pending application Ser. No. 07/342,311 filed on Apr. 24, 1989, now abandoned.
The present invention relates to a system and method for processing spectral information used to aid in the diagnosis of diseased tissue. More particularly, it relates to a method for collecting and displaying the excitation and emission spectra resulting from the laser-induced-fluorescence of tissue.
Methods utilizing the laser-induced-fluorescence ("LIF") of tissue have been developed which permit the characterization of the tissue being examined. This technique has traditionally employed the use of fluorescing agents or dyes which are introduced or applied to the tissue of interest which is then irradiated to induce fluorescence and produce a spectrum that can be used to distinguish diseased from normal tissue. The emission spectra obtained through these methods are normally plotted as intensity versus emission wavelength for a given excitation wavelength. These graphical displays can provide information regarding the diseased condition of tissue as specific peaks in the spectra of abnormal tissue appear which are not present in normal tissue.
Laser catheter systems have also been developed, often in conjunction with known techniques for using fluorescence to aid in diagnosis, for the purpose of inserting a light transmitting device into the human body where laser radiation can be directed onto tissue adjacent the distal end of the catheter to induce fluorescence. The light emitted by the tissue is transmitted along the catheter and analyzed at the proximal end thereof to produce an emission spectrum of the irradiated tissue.
The problem with these standard spectra is that they are highly dependent upon the excitation wavelength that is used such that a highly fragmented view of the spectral characteristics of the tissue is provided. Thus, a more complete method of generating diagnostic information utilizing LIF spectroscopy is needed that more fully characterizes the spectral features of tissue.
The present invention relates to a system for characterizing tissue fluorescence in the ultraviolet and throughout the visible for the purpose of generating diagnostically useful information. The present system provides the ability to look at fluorescence over a wide range of excitation and emission wavelengths. Such a broad survey is important in fully characterizing the spectroscopic differences between tissue types as well as in aiding in the identification of tissue fluorophores whose presence is correlated with known normal and abnormal states of tissue.
The intensity of fluorescence depends on three parameters: the radiative properties of the fluorophores within the tissue; the wavelength of the exciting light; and the wavelength of the emitted fluorescence. Two types of scans are typically used when recording fluorescence intensity: emission scans (spectra), in which the excitation wavelength is held constant and the emission wavelength is varied, and excitation scans (spectra), in which the emission wavelength is constant and the excitation is varied. Either type of scan alone contains useful information about the tissue constituents; however, both excitation and emission profiles are needed for a full characterization of fluorescence. In fact, a complete fluorescence characterization involves recording the fluorescence intensity for each possible pair of excitation and emission wavelengths.
Typically, emission (or excitation) scans are presented as two dimensional plots with emission (or excitation) wavelengths running along one axis and fluorescence intensity running along the other axis. In order to display intensity for each possible pair of excitation and emission wavelengths, a 3-dimensional plot of intensity vs. excitation and emission is one alternative for displaying the information for analysis. There are also two methods employed for representing such plots in two dimensions: perspective drawing and contour (topographic) mapping. In a preferred embodiment, contour maps are employed to display the data as they provide for viewing many of the important features on one plot.
This method is employed in conjunction with laser catheter systems used to induce fluorescence in bodily tissue both in vitro and in vivo without the use of fluorescence enhancing agents, also referred to herein as "autofluorescence". The procedure is illustrated using data collected on excised tissue samples, including artery wall, gastrointestinal tissue and bladder tissue, but are usefully applied to all types of tissue and the abnormal or diseased conditions which can be differentiated by optical characteristics.
In particular, fluorophores present in the tissue under study, whose concentration varies with the condition of the tissue, have been associated with specific features of the contour spectra. This correlation between the contour spectra and the chemical constituents of the tissue is useful in the construction of diagnostic methods which can systematically differentiate tissue type and condition.
The above and other features of the invention, including various novel details in the methods described and certain combinations thereof, will now be more particularly described with reference to the accompanying drawings and pointed out in the claims. It will be understood that the particular methods of diagnosis embodying the invention are shown by way of illustration only and not as a limitation of the invention. The principle features of the invention may be employed in various embodiments without departing from the scope of the invention.
FIG. 1 is a schematic diagram of an apparatus used in conjunction with the present invention.
FIG. 2 illustrates a contour map of morphologically normal aorta.
FIG. 3a presents four emission scans from the region about line A-B of FIG. 2.
FIG. 3b presents emission scans from line A-C in FIG. 2.
FIGS. 4a and 4b present a contour map and a perspective view of an excitation emission matrix of fluorescence intensity of normal aorta.
FIGS. 5a and 5b show a contour map and a perspective view, respectively, of an averaged excitation-emission matrix of fibrous aortic tissue.
FIGS. 6a and 6b show a contour map and a perspective view, respectively, of an averaged excitation-emission matrix of calcified aortic tissue.
FIGS. 7a and 7b show a contour map and a perspective view, respectively, of an excitation-emission matrix of fatty aortic tissue.
FIGS. 8a and 8b show an absorption spectrum and a contour map, respectively, of hemoglobin.
FIGS. 9a and 9b show contour maps of bulk aorta before and after the sample is soaked in saline.
FIG. 10 shows a contour map of the attenuation matrix of hemoglobin.
FIGS. 11a and 11b show contour maps of aortic tissue after soaking to remove hemoglobin, and after the addition of the effects of hemoglobin using the hemoglobin absorption matrix.
FIG. 12 illustrates a contour 12 of powdered type 1 bovine collagen.
FIGS. 13a and 13b show average fluorescence contour maps of normal human colon tissue.
FIGS. 14a and 14b show average fluorescence contour maps for adenomatous human colon tissue.
FIG. 15 shows the ratio of an average contour map for adenomatous polyp to an average contour map for normal gastrointestinal tissue.
FIG. 16 shows the map of FIG. 15 where the contour line density is increased by a factor of two to show more detail.
FIG. 17 illustrates a diagnostic algorithm for differentiating adenomatous from normal colon tissue based upon a ratio of maps at an excitation wavelength of 330 nanometers and an emission wavelength of 385 nanometers.
FIG. 18 illustrates a diagnostic algorithm based upon an excitation wavelength of 440 nanometers and an emission wavelength of 480 nanometers.
FIG. 19 illustrates a binary type diagnostic algorithm.
FIGS. 20a and 20b show average contour maps on different scales of normal bladder tissue.
FIGS. 21a and 21b show average contour maps on two different scales of bladder tumor.
FIG. 22 shows a ratio of contour maps for bladder tumor and normal bladder tissue.
FIG. 23 shows the map of FIG. 22 with a greater contour line density.
FIG. 24 shows a binary diagnostic algorithm to differentiate bladder tumor from normal bladder tissue.
FIG. 1 illustrates a preferred embodiment of the system that is used in generating and processing matrices of fluorescence intensity obtained as a function of both excitation and emission wavelengths. Light source 10 can be a broadband source such as a Xenon arc lamp. However, a tunable laser can also be employed to provide excitation radiation of variable wavelength. A double monochromator 12 subject to scan control 14 directs radiation of selected wavelength through optical fiber 16 onto the tissue sample 22. Collection fibers 18 collect the fluorescent radiation emitted by the sample 22 and direct it through collection optics 20 and into a second double monochromator 24. Photomultiplier 26 then detects the radiation and generates a signal that is forwarded to computer 28 for processing and display. Computer 28, via line 30, can be used to control the scanning parameters of the two monochromators 12 and 24.
The optical probe or catheter 32 can also be used in vivo within the human body to perform diagnostic scans on living tissue. The methods of the present invention may be used in conjunction with the laser catheter systems disclosed in U.S. Pat. No. 4,718,417, incorporated herein by reference.
Fluorescence intensity from normal aorta was recorded over a range of from 250 to 700 nm every 5 nm for both excitation and emission. The system used for this type of measurement is easily tuned over a large range of excitations. The system can use a rhodamine solution as a reference, so that differences in intensity of the exciting light at different wavelengths are automatically removed from the spectra. This makes it possible to obtain fluorescence intensities over a large range of excitations and emissions on a single sample of tissue in a reasonable amount of time. Gratings blazed at 250 nm have been used so that emission spectra can be taken from 250 to 700 nm.
To generate the data, emission scans were taken with excitations of 250 to 500 nm every 5 nm. The emission ranges ran from the excitation +12.5 nm to 697.5 nm every 5 nm. The FIGURES described below are generated by sequential acquisition of emission scans; however, excitation scans could be used as well to display the relationship between excitation and emission. The FWHM (full width-half maximum) of the excitation source was 2 nm, and the emission FWHM was 3 nm. An integration time of 1 second at each point yielded a reasonable signal to noise ratio for all scans.
FIG. 2 shows the contour map that was generated from a sample of morphologically normal aorta. The map shows five distinct peaks (labeled A-E in FIG. 2). Each peak potentially represents a distinct fluorophore; however, it is known that fluorescence reabsorption in the tissue can create artificial peaks in emission spectra. On the contour map, such reabsorption valleys should appear as depressions at constant emission wavelength, since the wavelength of reabsorption does not depend on excitation. The three dashed vertical lines in FIG. 2 are examples of such reabsorption. The two lines near 570 nm emission represent absorption due to oxy-hemoglobin, while the line near 415 nm is the Soret band of heme. Based on this interpretation, the two peaks D and E are due to a single fluorophore which is known to be elastin/collagen. The peaks B and C may also be due to a single fluorophore, although the fact that they are slightly shifted in excitation from one another supports the notion that the peaks are due to two distinct fluorophores.
Horizontal lines, that is, lines of constant excitation, on the map represent emission scans. Four emission scans from the region designated by line A-B in FIG. 2 are shown in FIG. 3a. These scans are very similar to those with 476 nm excitation. The two peaks at 560 and 600 nm are artificial in that they are created by the reabsorption valleys at 540 and 580 nm, as was surmised from the contour map.
Emission scans from line A-C are shown in FIG. 3b. As can be seen from the contour map, the intensity of fluorophore A, emitting at 340 nm, is strongly dependent on excitation wavelength near 300 nm. This is vident from the very close spacing of the contour lines in this region. This fluorophore has been identified as tryptophan. The Soret valley at 415 nm is also seen in these emission scans, as is the emergence of another peak (B) at 390 nm, as excitation wavelength is made longer. Based on spectra from thin samples of artery, peak C (at 450 nm emission) was assumed to be artificially created by the Soret valley, so that peaks B and C were assigned to a single fluorophore. However, as the contour map reveals, these peaks occur at slightly different excitations, and it is possible that two distinct fluorophores are being observed.
This system has been used to determine optimal excitation and emission wavelengths for differentiating normal and atherosclerotic aorta. Also, contour maps of fibrous, fatty and calcified plaques have been constructed. By normalizing these maps and then subtracting them from, or ratioing them, to a normalized map of normal aorta, excitation and emission wavelengths at which fluorescence lineshapes of normal and diseased tissue are most different can be easily identified.
FIGS. 4-7 present data collected as excitation-emission matrices (EEM's) of bulk samples of normal and pathological human aorta tissue. This data, which is presented in the form of contour maps as well as perspective drawings is used to determine an optimum wavelength for distinguishing between normal and pathological tissue.
Tissue samples are classified as either normal, fibrous, fatty, or calcified. In all, there were nine normal samples run from five different patients six calcified samples which were all from the same patient, eight fibrous samples taken from four different patients, and two samples of fatty tissue from the same patient.
The EEM's of each tissue type were averaged with the exception of the fatty sample shown in FIG. 7
The main features of the EEM's of the normal samples of FIGS. 4a and 4b are the dominant tryptophan peak in the uv and the absorption valleys at 415 nm, which are believed to be caused by the presence of hemoglobin in the tissue. There is also weaker fluorescence in the visible range, which is primarily due to chromophores within the collagen and elastin. The most noticeable difference between the EEM's of the normal and fibrous tissue (at FIGS. 5a and 5b) is that there is greater fluorescence at the longer wavelengths in normal compared to fibrous. There also appears to be a difference in the location of the peak of the fluorescence due to chromophores within the collagen, but this may be the result of less hemoglobin absorption in the fibrous tissue. One difference between the calcified tissue shown in FIGS. 6a and 6b and the normal tissue is that the fluorescence peak due to tryptophan is about a factor of two lower in the calcified tissue. In addition, the fluorescence due to chromophores within the collagen and elastin is two to three times greater in the calcified tissue, and there is also less absorption at 415 nm. One of the chromophores found within the collagen or elastin morphologic structures is pyridinoline which is known to fluoresce in the range 400-420 nm when excited by radiation in the range of 360-370 nm.
Hemoglobin (Hb) plays an important role in in vitro aorta EEM's. The large Soret absorption band at 416 nm is responsible for the deep valleys seen in the contour map both at excitations and emissions around 416 nm. Oxyhemoglobin also produces the minor valleys near 540 and 580 nm. Note that heme is one of the chromophores found in hemoglobin. Heme has an absorption region centered around 560 nm. This conclusion is supported by the following observations:
1) The absorption spectrum of hemoglobin has peaks coincident with the valleys mentioned above (FIGS. 8a and 8b).
2) In vitro aorta samples have typically been exposed to lysed red blood cells and, therefore, free Hb which can readily diffuse into the tissue.
3) These valleys are absent in 10 μm sections of intima and media. The effects of absorption on LIF are negligible in these thin sections.
4) These valleys can be nearly eliminated by soaking an in vitro bulk aorta sample in saline before collecting the spectra (FIGS. 9a and 9b). This soaking removes most of the Hb, which can freely diffuse from the tissue.
The physical basis for these valleys is quite simple: a portion of the incident excitation light as well as the emitted fluorescence is reabsorbed by the Hb, causing a reduction in the fluorescence intensity. This can be clearly seen from the single layer tissue fluorescence model, in which the observed fluorescence intensity S(λx,λm) can be written ##EQU1## where F(λx,λm) is the "intrinsic" tissue fluorescence, i.e. the tissue fluorescence from a thin section, free of absorption effects; xHb AHb (λx,λm)=μHb (λx) +μHb (λm), where AHb represents the attenuation spectrum of Hb (and similarly for SP, where SP refers to fixed tissue absorbers). AHb (λx,λm) can be thought of as the normalized attenuation matrix of Hb, with xHb representing its concentration; it can be generated from the Hb absorption spectrum if effects of scattering are neglected. A contour map of AHb (λx,λm), which clearly shows the Soret absorption bands, is shown in FIG. 10.
Equation (1) can be rewritten ##EQU2## where S0 (λx,λm) is the fluorescence observed in the absence of Hb(xHb= 0). By making the crude assumption that ASP is a constant (not dependent on wavelength) over the entire EEM, by using values of xHb and xSP ASP determined with 476 nm excitation, and by using the calculated Hb absorption matrix, the effect of Hb absorption can be reproduced from the soaked aorta EEM (xHb= 0) by "dividing" Hb absorption matrix into it in the manner specified by Eq. 2. The result is displayed in FIGS. 11a and 11b. The structure of the aorta EEM with Hb (before soaking) is recovered, although peak intensities, especially in the ultraviolet, are smaller than in the actual EEM.
Using this method, Hb absorption effects can also be produced in an ex vivo aorta sample. The EEM of the ex vivo sample which has presumably not been exposed to free Hb, is quite similar to that of the soaked aorta. By dividing the Hb absorption matrix into it in the manner of Eq. 2, an EEM very similar to that of Hb-containing in vitro aorta is produced.
This method of correcting for the presence of absorbers within the tissue being examined can be applied to other absorbing components. The removal of the effects of absorption can assist in providing a clearer spectrum in which all of the avisibile information regarding tissue fluorescence can be recovered.
The system also assists in identifying the chromophores which contribute to arterial tissue fluorescence spectra. Contour maps provide very useful insight about the number and nature of tissue chromophores. To separate contributions from different chromophores, maps can be obtained from thin tissue sections, which contain a limited number of chromophores (e.g. ceroid in necrotic core) and are free of reabsorption effects. Also maps of pure compounds, which are suspected tissue chromophores, can be constructed for comparison with tissue maps. For example, FIG. 12 contains a map of powdered type 1 bovine collagen. Other components studied include chromophores or structures containing chromophores such as elastin, tryptophan, hemoglobin and flavoprotein.
Although type 1 collagen has emission in the same region as does normal aorta, there are several important differences. Some of these are due to reabsorption of hemoglobin; the collagen map does not show valleys at 420, 540 and 580 nm. However, other differences are not related to reabsorption, and indicate that tissue fluorescence in this region contains contributions from chromophores other than those present in type 1 collagen.
The methods of the present invention have been used to differentiate normal and pathologic tissues in human colon and urinary bladder with excitation wavelengths ranging from 250-500 nm, utilizing fluorescence contour maps. This contour mapping serves to identify optimal excitation wavelengths for differentiating normal and pathologic tissue fluorescence spectra and to identify tissue chromophores contributing to the fluorescence of normal and pathologic tissues.
Fluorescence contour maps were collected from 18 colon specimens and 15 urinary bladder specimens. Fluorescence contour maps were constructed from a series of fluorescence emission spectra recorded using a spectrofluorimeter. Excitation wavelengths were varied in 10 nm steps from 250 to 500 nm. Fluorescence was collected at 5 nm intervals from λexc+10 nm to 2λexc-10 nm. Incident beam size was ˜2×3 mm, smaller than the surface area of all tissue samples, thus absolute intensity information has been preserved in the analysis of this data. To correct for day to day variations in the spectrofluorimeter alignment, all data has been divided by a fluorescence intensity standard which is run each day. Emission gratings were blazed at 250 nm. All data presented here has been corrected for the non-uniform spectral response of the collection system.
The following method of data analysis was employed for both colon and bladder tissues. An average normal contour map NA (λx,λm), and an average pathologic contour map PA (λx,λm) were calculated and were plotted on a log scale with contours ranging from 50 to 0.5. To compare contour maps of normal and pathologic tissues, a ratio of the average contour maps was constructed as: ##EQU3## and was plotted on a linear scale with contours varying from 2.0 to 0.2. Here, a contour at 1.0 indicates regions in which the fluorescence emission from normal and pathologic tissues is the same, while contours at values greater (less) than 1.0 indicate regions where the emission from pathologic tissue is greater (less) than that from normal tissues Regions of greatest difference in the fluorescence spectra of normal and pathologic tissues were assessed from this average ratio map. This information was used in defining a process for determination of tissue type.
To assess how the variability of individual tissues affected this comparison, the following ratio maps were constructed for each individual normal and pathologic sample: ##EQU4## Data from these individual ratio maps was used to test processes suggested in the above data analysis procedure.
FIGS. 13 and 14 show average fluorescence contour maps of normal and adenomatous human colon tissue. In the normal tissue fluorescence contour map, several major fluorescence and absorption bands can be recognized, as summarized in Table 1. Similarly, Table 2 lists the major absorption and fluorescence bands found in the adenomatous fluorescence contour map.
TABLE 1______________________________________Average Normal Colon Tissue Fluorescence(λx, λm) Intensity Chromophore______________________________________(285, 340) 50.0 Tryptophan(330, 385) 5.0 Chromophore Within Collagen(315, 430) 2.5 4-Pyridoxic Acid(345, 465) 5.0 NAD(P)H(460, 520) 4.5 Flavin(λ, 420) (420, λ) Hemoglobin (Heme)(λ, 540) (λ, 580)______________________________________
TABLE 2______________________________________Average Adenomatous Colon Tissue Fluorescence(λx, λm) Intensity Chromophore______________________________________(285, 340) 50.0 Tryptophan(340, 470) 2.5 NAD(P)H(460, 520) 2.5 Flavin(λ,420) (420, λ) Hemoglobin (Heme)(λ, 540) (λ, 580)______________________________________
A comparison of these two tables points out several of the interesting differences in the fluorescence contour maps of normal and adenomatous tissues Both tissues exhibit tryptophan fluorescence. Qualitatively, the shape and peak fluorescence intensity of this band is very similar for both types of tissue Two additional fluorescence bands appear to be present in the normal tissue fluorescence contour map at (330,385) and (315,430). In the visible region of the spectrum, the fluorescence intensity of normal tissues is approximately 2× that of adenomatous tissues. In particular, both tissues show a band near (340,470); this band is 2× higher in normal tissue. In addition, it is more peaked, and slightly shifted in normal tissue relative to adenomatous tissue. Both tissues show a peak at (460,520), which is 1.8× more intense in normal tissue.
These differences are highlighted in FIG. 15, which shows the ratio of the two average contour maps, with contours drawn linearly from 2.0 to 0.2. Greater detail is shown in FIG. 16, with contours drawn from 1.0 to 0.1. Again contours at 1.0 indicate regions where normal and adenomatous tissues exhibit equal fluorescence intensities, while contours greater (less) than 1.0 indicate regions where adenomatous tissue fluorescence is greater (less) than normal tissue fluorescence. In the region of tryptophan fluorescence, a contour with a value of 1.0 is shown, indicating the similarity of tryptophan fluorescence in normal and adenomatous tissues. A valley is present at (335,385) with a contour level of 0.3 indicating the additional fluorescence band present in normal tissue at this location. A valley is present at (390,430) with a contour of 0.8. Additional valleys are present at (400,495), (440,480), (430,600) and (430,670). These are summarized in Table 3.
TABLE 3______________________________________Average Ratio Map, Colon Tissue(λx, λm) .sup.R AVG.sup.(λ x, .sup.λ m.sup.) Chromophore______________________________________(330, 385) 0.3 Chromophore Within Collagen(390, 430) 0.8 Pyridoxic Acid Lactone(400, 495) 0.4 ?(440, 480) 0.4 ?(430, 600) 0.7 ?(430, 670) 0.8 ?______________________________________
The values of the individual ratio maps at these locations of (λx,λm), can be divided by the intensity of the ratio map at (290,340). Two of these values, at (330,385) and (440,480), independently provided useful diagnostics for differentiating normal and adenomatous tissues (FIGS. 17 and 18). In addition, a binary scheme utilizing information at (390,430) and (330,385) provided an accurate diagnostic process (FIG. 19).
FIGS. 20 and 21 show average fluorescence contour maps of normal bladder wall and tumor. Major fluorescence and absorption bands are summaried in Tables 4 and 5. Again, in the region of tryptophan fluorescence both normal and tumor tissues have similar emission. Although both tissues show a fluorescence band at (325,385), it is 3× stronger in normal tissue. Both tissues show fluorescence peaks at (350,470) with normal tissues exhibiting 2× as much fluorescence intensity. Also at (470,520) the fluorescence of normal tissue is 2× as high as that of tumor tissue. The average tumor map exhibits a unique peak at (315,430).
TABLE 4______________________________________Average Normal Bladder Tissue Fluorescence(λx, λm) Intensity Chromophore______________________________________(285, 340) 50.0 Tryptophan(325, 385) 15.0 Chromophore Within Collagen(350, 470) 10.0 NAD(P)H(470, 520) 10.0 Flavin(λ, 420) (420, λ) Hemoglobin (Heme)(λ, 540) (λ, 580)______________________________________
TABLE 5______________________________________Average Bladder Tumor Fluorescence(λx, λm) Intensity Chromophore______________________________________(285, 340) 50.0 Tryptophan(330, 385) 5.0 Chromophore Within Collagen(315, 430) 3.0 4-Pyridoxic Acid(350, 470) 5.0 NAD(P)H(460, 515) 5.0 Flavin(λ, 420) (420, λ) Hemoglobin (Heme)(λ, 540) (λ, 580)______________________________________
These differences are highlighted in FIGS. 22 and 23 which show the ratio contour map of tumor and normal bladder tissue for two sets of contours (2.0-0.2, 1.0-0.1). Table 6 summarizes the valleys present in this ratio map. Valleys are present at (330,385), (370,435), (400,495), (450,485), (420,640), and (390,670). Values of the individual ratio maps at these locations can be divided by the value of the tryptophan peak (290,340). FIG. 24 shows an example of a diagnostic procedure which can be defined from this data.
TABLE 6______________________________________Average Ratio Map, Bladder Tissue(λx, λm) .sup.R AVG.sup.(λ x, .sup.λ m.sup.) Chromophore______________________________________(330, 385) 0.4 Chromophore Within Collagen(370, 435) 0.8 Pyridoxic Acid Lactone(400, 495) 0.5 ?(450, 485) 0.4 ?(420, 640) 0.9 ?(390, 670) 0.6 ?______________________________________
Because of the voluminous information in the 2-D plots, a model is useful in interpreting the data. Even if the types and concentrations of all chromophores were known, quenching, spectral shifts, and energy transfer due to the local environment would alter a calculated spectrum. But, in spite of these many unknowns, a "landscape" model of chromophore behavior does provide some general insights for locating distinctive features for comparative spectral diagnosis.
The model begins with the reasonable assumption that tissue contains a few relatively strongly fluorescing chromophores, a background of weaker ones, and absorbers which are probably non-fluorescent. The strong chromophores, with relatively high quantum yields or concentrations (or both), will generate "peaks" on the contour plot. In addition, these chromophores generally have a broad base which tends toward shorter wavelengths for excitation; and due to the general anharmonicity of higher vibrational levels, it tends toward longer wavelengths for emission. Combining with the weaker chromophores, this forms an average elevation of signal background from which the peaks arise. The absorbers cut vertically and horizontally across the spectral terrain. The percent decrease along the line should be approximately constant to the extent that the penetration depth is constant. This is distinguishable from a "pass" between two spectral peaks, which is just lesser fluorescence, not absorption. Thin sections will be quite helpful in identifying absorption features by their absence.
Distinguishing diseased vs. healthy tissue is essentially distinguishing one set of chromophore signals from another. If two tissues have different amounts of one chromophore, then the corresponding absolute signals might be measured; however, this is dependent on collection geometry. Comparisons, or ratios, are less geometry dependent, but appropriate positions on the 2-D surface need to be selected. The data is normalized so as to again avoid geometry-dependent ratios.
The spectral landscape model has three regions: 1) fluorescent peaks, 2) an average elevation, or plateau, and 3) absorption valleys. Of these, region 1 is the most appealing as a discriminant for tissue type, as it would show a characteristic chromophore. Region 3 is susceptible to variability or leaching as has been shown for the case of heme, and region 2, being comprised of fluorescence from several chromophores, is likely to have the least variation overall. Signal change due to a change in one of the chromophores would be diminished by the fraction of the total signal contributed by that chromophore. In other words, instead of comparing absolute peak heights, they should first be normalized relative to the average elevation. Ideally, normalization would be relative to selected regions thought to be "average"; a practical compromise is the average height from the total integrated signal of the entire plot. Peaks then have signals >1, and valleys generally <1. The comparison signal Rλ for each set of excitation and emission wavelengths, equals the diseased signal Dλ, divided by the normal tissue signal, Nλ.
If subtraction is used instead of the ratio, then this number should be normalized to the signal strength at that wavelength to indicate the fractional, rather than absolute, change:
where ΔDλ=Dλ-Nλ and therefore Sλ=Rλ-1.
This gives the normalized differential signal Sλ. N is in the denominator, since it is desirable to determine the deviation of the diseased tissue from normal. When the "peak" value is selected, it should be integrated over the top 10%-20% of the peak, thereby incorporating a substantial volume of the fluorescence signal; otherwise, data is discarded, and the noise level is increased.
An alternative approach is to normalize two contour plots to the same chromophore peak, then ratio them. This would compare amplitudes of other peaks to the first. However, the ratioed contour plot is dependent on which peak is selected for normalization, and the information from the rest of the plot, which provides the total integrated signal, is in effect, unused.
Additional information is contained in the peak shape. If the different environments of the tissue cause spectral shifts, then this may be emphasized by ratioing normalized peaks on two contour plots. In this case a smaller integrated area may be better for normalization. Deviations from unity will indicate different slopes or shapes.
To avoid overemphasizing weaker parts of the spectrum, a weighting factor may be introduced: Assuming that the signal to noise ratio varies as the square root of the signal, the ratio signal should be multiplied by the square root of Nλ to yield Wλ, the weighted normalized ratio contour plot comparing the two tissue types.
These computations should be straightforward for numerical peak comparison. Large differences in regions where the fluorescence is weak will be de-emphasized.
|Patente citada||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US4178917 *||3 Ene 1979||18 Dic 1979||Shapiro Howard M||Method and system for non-invasive detection of zinc protoporphyrin in erythrocytes|
|US4449535 *||25 Mar 1982||22 May 1984||Compagnie Industrielle Des Lasers Cilas Alcatel||Apparatus for measuring in situ the state of oxidation-reduction of a living organ|
|US4479499 *||29 Ene 1982||30 Oct 1984||Alfano Robert R||Method and apparatus for detecting the presence of caries in teeth using visible light|
|US4556057 *||11 Mar 1983||3 Dic 1985||Hamamatsu Tv Co., Ltd.||Cancer diagnosis device utilizing laser beam pulses|
|US4648892 *||22 Mar 1985||10 Mar 1987||Massachusetts Institute Of Technology||Method for making optical shield for a laser catheter|
|US4768516 *||18 Feb 1986||6 Sep 1988||Somanetics Corporation||Method and apparatus for in vivo evaluation of tissue composition|
|US4785806 *||8 Ene 1987||22 Nov 1988||Yale University||Laser ablation process and apparatus|
|US4786813 *||22 Oct 1985||22 Nov 1988||Hightech Network Sci Ab||Fluorescence imaging system|
|US4894547 *||28 Sep 1987||16 Ene 1990||Yale University||Optical method and apparatus for detecting and measuring aging, photoaging, dermal disease and pigmentation in skin|
|US4930516 *||25 Abr 1988||5 Jun 1990||Alfano Robert R||Method for detecting cancerous tissue using visible native luminescence|
|US4957114 *||28 Jun 1988||18 Sep 1990||Kun Zeng||Diagnostic apparatus for intrinsic fluorescence of malignant tumor|
|US5003977 *||9 Mar 1989||2 Abr 1991||Agency Of Industrial Science And Technology||Device for analyzing fluorescent light signals|
|US5042494 *||4 Dic 1989||27 Ago 1991||Alfano Robert R||Method and apparatus for detecting cancerous tissue using luminescence excitation spectra|
|US5046501 *||18 Ene 1989||10 Sep 1991||Wayne State University||Atherosclerotic identification|
|US5062431 *||30 Mar 1990||5 Nov 1991||Health Research, Inc.||In vivo fluorescence photometer|
|1||*||Pottier et al., Photochemistry & Photobiology, vol. 44, No. 5, pp. 679 687 (1986).|
|2||Pottier et al., Photochemistry & Photobiology, vol. 44, No. 5, pp. 679-687 (1986).|
|3||Publication, "Tumour Localization by Means of Laser-Induced Fluorescence in Hematoporphyrin Derivative (HPD) Bearing Tissue".|
|4||*||Publication, Tumour Localization by Means of Laser Induced Fluorescence in Hematoporphyrin Derivative (HPD) Bearing Tissue .|
|Patente citante||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US5345941 *||1 Mar 1993||13 Sep 1994||Massachusetts Institute Of Technology||Contour mapping of spectral diagnostics|
|US5363855 *||25 Ago 1992||15 Nov 1994||Rutgers University||Pressure waveform monitor|
|US5421337 *||29 Mar 1994||6 Jun 1995||Massachusetts Institute Of Technology||Spectral diagnosis of diseased tissue|
|US5421339 *||12 May 1993||6 Jun 1995||Board Of Regents, The University Of Texas System||Diagnosis of dysplasia using laser induced fluoroescence|
|US5612540 *||31 Mar 1995||18 Mar 1997||Board Of Regents, The University Of Texas Systems||Optical method for the detection of cervical neoplasias using fluorescence spectroscopy|
|US5640957 *||9 Jun 1995||24 Jun 1997||Instruments Sa, Inc.||Ultraviolet radiation protection evaluator|
|US5697373 *||14 Mar 1995||16 Dic 1997||Board Of Regents, The University Of Texas System||Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies|
|US5699795 *||31 Mar 1995||23 Dic 1997||Board Of Regents, The University Of Texas System||Optical probe for the detection of cervical neoplasia using fluorescence spectroscopy and apparatus incorporating same|
|US5713364 *||1 Ago 1995||3 Feb 1998||Medispectra, Inc.||Spectral volume microprobe analysis of materials|
|US5813987 *||24 Dic 1996||29 Sep 1998||Medispectra, Inc.||Spectral volume microprobe for analysis of materials|
|US5842995 *||28 Jun 1996||1 Dic 1998||Board Of Regents, The Univerisity Of Texas System||Spectroscopic probe for in vivo measurement of raman signals|
|US5984861 *||29 Sep 1997||16 Nov 1999||Boston Scientific Corporation||Endofluorescence imaging module for an endoscope|
|US5991653 *||19 Jun 1996||23 Nov 1999||Board Of Regents, The University Of Texas System||Near-infrared raman spectroscopy for in vitro and in vivo detection of cervical precancers|
|US6055451 *||12 Dic 1997||25 Abr 2000||Spectrx, Inc.||Apparatus and method for determining tissue characteristics|
|US6095982 *||11 Dic 1997||1 Ago 2000||Board Of Regents, The University Of Texas System||Spectroscopic method and apparatus for optically detecting abnormal mammalian epithelial tissue|
|US6096065 *||29 Sep 1997||1 Ago 2000||Boston Scientific Corporation||Sheath for tissue spectroscopy|
|US6104945 *||13 Ene 1997||15 Ago 2000||Medispectra, Inc.||Spectral volume microprobe arrays|
|US6119031 *||22 Jul 1997||12 Sep 2000||Boston Scientific Corporation||Miniature spectrometer|
|US6135965 *||2 Dic 1996||24 Oct 2000||Board Of Regents, The University Of Texas System||Spectroscopic detection of cervical pre-cancer using radial basis function networks|
|US6174291||9 Mar 1998||16 Ene 2001||Spectrascience, Inc.||Optical biopsy system and methods for tissue diagnosis|
|US6185443||29 Sep 1997||6 Feb 2001||Boston Scientific Corporation||Visible display for an interventional device|
|US6241672 *||18 Dic 1997||5 Jun 2001||University Of Washington||Method and apparatus for optically imaging solid tumor tissue|
|US6289229||19 Ene 1999||11 Sep 2001||Scimed Life Systems, Inc.||Readable probe array for in vivo use|
|US6324418||29 Sep 1997||27 Nov 2001||Boston Scientific Corporation||Portable tissue spectroscopy apparatus and method|
|US6343227||6 Ene 2000||29 Ene 2002||Boston Scientific Corporation||Miniature spectrometer|
|US6364831||18 Ago 1999||2 Abr 2002||Boston Scientific Corporation||Endofluorescence imaging module for an endoscope|
|US6383209||1 Jun 2000||7 May 2002||Boston Scientific Corporation||Sheath for tissue spectroscopy|
|US6385484||15 Dic 2000||7 May 2002||Medispectra, Inc.||Spectroscopic system employing a plurality of data types|
|US6393315||11 Sep 1998||21 May 2002||Communaute Europeenne||Detecting and mapping of inflamed zones in a living tissue|
|US6405073||18 Oct 2000||11 Jun 2002||Scimed Life Systems, Inc.||Miniature spectrometer system and method|
|US6411838||22 Dic 1999||25 Jun 2002||Medispectra, Inc.||Systems and methods for optical examination of samples|
|US6671540 *||3 Ago 1999||30 Dic 2003||Daryl W. Hochman||Methods and systems for detecting abnormal tissue using spectroscopic techniques|
|US6697652||19 Ene 2001||24 Feb 2004||Massachusetts Institute Of Technology||Fluorescence, reflectance and light scattering spectroscopy for measuring tissue|
|US6697666||6 Mar 2000||24 Feb 2004||Board Of Regents, The University Of Texas System||Apparatus for the characterization of tissue of epithelial lined viscus|
|US6760613||24 Jun 2002||6 Jul 2004||Medispectra, Inc.||Substantially monostatic, substantially confocal optical systems for examination of samples|
|US6768918||10 Jul 2002||27 Jul 2004||Medispectra, Inc.||Fluorescent fiberoptic probe for tissue health discrimination and method of use thereof|
|US6818903||13 Sep 2002||16 Nov 2004||Medispectra, Inc.||Method and apparatus for identifying spectral artifacts|
|US6826422||11 Ene 2000||30 Nov 2004||Medispectra, Inc.||Spectral volume microprobe arrays|
|US6839661||15 Dic 2000||4 Ene 2005||Medispectra, Inc.||System for normalizing spectra|
|US6847490||9 Jun 2000||25 Ene 2005||Medispectra, Inc.||Optical probe accessory device for use in vivo diagnostic procedures|
|US6882875||18 Oct 2000||19 Abr 2005||Boston Scientific Corporation||Visible display for an interventional device|
|US6902935||15 Dic 2000||7 Jun 2005||Medispectra, Inc.||Methods of monitoring effects of chemical agents on a sample|
|US6912412||18 Ene 2002||28 Jun 2005||Massachusetts Institute Of Technology||System and methods of fluorescence, reflectance and light scattering spectroscopy for measuring tissue characteristics|
|US6933154||15 Nov 2002||23 Ago 2005||Medispectra, Inc.||Optimal windows for obtaining optical data for characterization of tissue samples|
|US7103401||10 Jul 2002||5 Sep 2006||Medispectra, Inc.||Colonic polyp discrimination by tissue fluorescence and fiberoptic probe|
|US7127282||12 Abr 2002||24 Oct 2006||Medispectra, Inc.||Optical methods and systems for rapid screening of the cervix|
|US7130672||25 Sep 2001||31 Oct 2006||Critisense Ltd.||Apparatus and method for monitoring tissue vitality parameters|
|US7136518||18 Abr 2003||14 Nov 2006||Medispectra, Inc.||Methods and apparatus for displaying diagnostic data|
|US7187810||18 Oct 2002||6 Mar 2007||Medispectra, Inc.||Methods and systems for correcting image misalignment|
|US7260248||15 Mar 2002||21 Ago 2007||Medispectra, Inc.||Image processing using measures of similarity|
|US7282723||18 Abr 2003||16 Oct 2007||Medispectra, Inc.||Methods and apparatus for processing spectral data for use in tissue characterization|
|US7302289||14 Jun 2001||27 Nov 2007||Scimed Life Systems, Inc.||Readable probe array for in-vivo use|
|US7307774||24 Ene 2006||11 Dic 2007||The Board Of Trustees Of The Leland Standford Junior University||Micro-optical analysis system and approach therefor|
|US7309867||18 Abr 2003||18 Dic 2007||Medispectra, Inc.||Methods and apparatus for characterization of tissue samples|
|US7310547||19 Jul 2004||18 Dic 2007||Medispectra, Inc.||Fluorescent fiberoptic probe for tissue health discrimination|
|US7313424||6 Mar 2003||25 Dic 2007||Critisense Ltd.||Diagnosis of body metabolic emergency state|
|US7459696||18 Abr 2003||2 Dic 2008||Schomacker Kevin T||Methods and apparatus for calibrating spectral data|
|US7469160||18 Abr 2003||23 Dic 2008||Banks Perry S||Methods and apparatus for evaluating image focus|
|US7499161||5 Jul 2006||3 Mar 2009||The Board Of Regents Of The University Of Texas System||Depth-resolved spectroscopy method and apparatus|
|US7899518 *||12 Sep 2005||1 Mar 2011||Masimo Laboratories, Inc.||Non-invasive tissue glucose level monitoring|
|US8005527||12 Dic 2007||23 Ago 2011||Luma Imaging Corporation||Method of determining a condition of a tissue|
|US8008283||17 Oct 2005||30 Ago 2011||Neurotherapeutics Pharma, Inc.||Methods and compositions for the treatment of neuropsychiatric disorders|
|US8126531||13 Dic 2001||28 Feb 2012||Boston Scientific Scimed, Inc.||Miniature spectrometer|
|US8140148||9 Ene 2007||20 Mar 2012||Boston Scientific Scimed Ltd.||Readable probe array for in vivo use|
|US8280484||30 Abr 2009||2 Oct 2012||The Invention Science Fund I, Llc||System, devices, and methods for detecting occlusions in a biological subject|
|US8317776||19 May 2008||27 Nov 2012||The Invention Science Fund I, Llc||Circulatory monitoring systems and methods|
|US8346346||18 Ene 2006||1 Ene 2013||The Board Of Trustees Of The Leland Stanford Junior University||Optical analysis system and approach therefor|
|US8380268||24 Jun 2005||19 Feb 2013||Massachusetts Institute Of Technology||System and methods of fluorescence, reflectance and light scattering spectroscopy for measuring tissue characteristics|
|US8403881||19 May 2008||26 Mar 2013||The Invention Science Fund I, Llc||Circulatory monitoring systems and methods|
|US8409132||20 Dic 2007||2 Abr 2013||The Invention Science Fund I, Llc||Treatment indications informed by a priori implant information|
|US8636670||13 May 2008||28 Ene 2014||The Invention Science Fund I, Llc||Circulatory monitoring systems and methods|
|US8660637||24 Ene 2012||25 Feb 2014||Boston Scientific Scimed, Inc.||Miniature spectrometer|
|US8722668||7 Abr 2005||13 May 2014||Daryl W. Hochman||Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders|
|US8788021||24 Ene 2006||22 Jul 2014||The Board Of Trustees Of The Leland Stanford Junior Univerity||Live being optical analysis system and approach|
|US8870813||22 May 2008||28 Oct 2014||The Invention Science Fund I, Llc||Circulatory monitoring systems and methods|
|US9161694||3 Jul 2012||20 Oct 2015||The Board Of Trustees Of The Leland Stanford Junior University||Optical analysis system and approach therefor|
|US9636020||2 Jul 2014||2 May 2017||The Board Of Trustees Of The Leland Stanford Junior University||Live being optical analysis system and approach|
|US9672471||30 Abr 2009||6 Jun 2017||Gearbox Llc||Systems, devices, and methods for detecting occlusions in a biological subject including spectral learning|
|US9717896||18 Dic 2007||1 Ago 2017||Gearbox, Llc||Treatment indications informed by a priori implant information|
|US20020102213 *||29 Ene 2002||1 Ago 2002||Yamato Scientific Co., Ltd.||Tissue mapping method and tissue map analyzer|
|US20020115918 *||13 Dic 2001||22 Ago 2002||Crowley Robert J.||Miniature spectrometer|
|US20020127735 *||5 Feb 2002||12 Sep 2002||Howard Kaufman||Methods of monitoring effects of chemical agents on a sample|
|US20020133073 *||8 Feb 2002||19 Sep 2002||Nordstrom Robert J.||Spectroscopic system employing a plurality of data types|
|US20020177777 *||12 Abr 2002||28 Nov 2002||Medispectra, Inc.||Optical methods and systems for rapid screening of the cervix|
|US20020197728 *||15 Dic 2000||26 Dic 2002||Howard Kaufman||Methods of monitoring effects of chemical agents on a sample|
|US20030095721 *||18 Oct 2002||22 May 2003||Thomas Clune||Methods and systems for correcting image misalignment|
|US20030135122 *||8 Ene 2003||17 Jul 2003||Spectrx, Inc.||Multi-modal optical tissue diagnostic system|
|US20030144585 *||15 Mar 2002||31 Jul 2003||Howard Kaufman||Image processing using measures of similarity|
|US20030207250 *||11 Abr 2003||6 Nov 2003||Medispectra, Inc.||Methods of diagnosing disease|
|US20030236458 *||24 Feb 2003||25 Dic 2003||Biophysica Llc||Spectroscopic systems and methods for detecting tissue properties|
|US20040007674 *||13 Sep 2002||15 Ene 2004||Schomacker Kevin T.||Method and apparatus for identifying spectral artifacts|
|US20040010375 *||18 Abr 2003||15 Ene 2004||Medispectra, Inc.||Methods and apparatus for processing spectral data for use in tissue characterization|
|US20040023406 *||15 Nov 2002||5 Feb 2004||Schomacker Kevin T.||Optimal windows for obtaining optical data for characterization of tissue samples|
|US20040054270 *||25 Sep 2001||18 Mar 2004||Eliahu Pewzner||Apparatus and method for monitoring tissue vitality parameters|
|US20040064053 *||30 Sep 2002||1 Abr 2004||Chang Sung K.||Diagnostic fluorescence and reflectance|
|US20040147843 *||26 Ago 2003||29 Jul 2004||Shabbir Bambot||System and method for determining tissue characteristics|
|US20040186382 *||4 Nov 2003||23 Sep 2004||Medispectra, Inc.||Spectral volume microprobe arrays|
|US20040206882 *||18 Abr 2003||21 Oct 2004||Medispectra, Inc.||Methods and apparatus for evaluating image focus|
|US20040207625 *||18 Abr 2003||21 Oct 2004||Medispectra, Inc.||Methods and apparatus for displaying diagnostic data|
|US20040208385 *||18 Abr 2003||21 Oct 2004||Medispectra, Inc.||Methods and apparatus for visually enhancing images|
|US20040208390 *||18 Abr 2003||21 Oct 2004||Medispectra, Inc.||Methods and apparatus for processing image data for use in tissue characterization|
|US20040209237 *||18 Abr 2003||21 Oct 2004||Medispectra, Inc.||Methods and apparatus for characterization of tissue samples|
|US20040214156 *||19 May 2004||28 Oct 2004||Medispectra, Inc.||Method and apparatus for identifying spectral artifacts|
|US20050033186 *||17 Jun 2004||10 Feb 2005||Medispectra, Inc.||Substantially monostatic, substantially confocal optical systems for examination of samples|
|US20050043635 *||19 Jul 2004||24 Feb 2005||Medispectra, Inc.||Fluorescent fiberoptic probe for tissue health discrimination and method of use thereof|
|US20050043929 *||18 Jun 2004||24 Feb 2005||Medispectra, Inc.||System for normalizing spectra|
|US20050064602 *||5 Ago 2004||24 Mar 2005||Medispectra, Inc.||Methods of monitoring effects of chemical agents on a sample|
|US20050159646 *||21 Dic 2004||21 Jul 2005||Medispectra, Inc.||Optical probe accessory device for use in in vivo diagnostic procedures|
|US20050234315 *||6 Mar 2003||20 Oct 2005||Avraham Mayevsky||Diagnosis of body metabolic emergency state|
|US20050267103 *||7 Abr 2005||1 Dic 2005||Cytoscan Sciences Llc||Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders|
|US20050288593 *||24 Jun 2005||29 Dic 2005||Massachusetts Institute Of Technology||System and methods of fluorescence, reflectance and light scattering spectroscopy for measuring tissue characteristics|
|US20060089350 *||17 Oct 2005||27 Abr 2006||Neurotherapeutics Pharma Llc||Methods and compositions for the treatment of neuropsychiatric disorders|
|US20060089556 *||12 Dic 2005||27 Abr 2006||Spectrx, Inc.||Multi-modal optical tissue diagnostic system|
|US20060161055 *||19 Dic 2005||20 Jul 2006||Critisense, Ltd.||Probe design|
|US20060195022 *||12 Sep 2005||31 Ago 2006||Pierre Trepagnier||Non-invasive tissue glucose level monitoring|
|US20070038120 *||5 Jul 2006||15 Feb 2007||The Board Of Regents Of The University Of Texas||Depth-Resolved Spectroscopy Method and Apparatus|
|US20070149526 *||13 Oct 2006||28 Jun 2007||Neurotherapeutics Pharma, L.L.C.||Diuretic and diuretic-like compound analogs|
|US20070167835 *||25 Jul 2006||19 Jul 2007||Massachusetts Institute Of Technology||Tri modal spectroscopic imaging|
|US20070173736 *||24 Jul 2006||26 Jul 2007||Femspec Llc||Apparatus and methods for endometrial biopsies|
|US20070179366 *||10 Oct 2006||2 Ago 2007||Critisense Ltd.||Apparatus and Method for Monitoring Tissue Vitality Parameters|
|US20080091110 *||12 Dic 2007||17 Abr 2008||Zelenchuk Alex R||Fluorescent Fiberoptic Probe for Tissue Health Discrimination and Method of Use Thereof|
|US20080225289 *||31 Mar 2008||18 Sep 2008||Chromagen, Inc.||Scanning spectrophotometer for high throughput fluorescence detection and fluorescence polarization|
|US20080309933 *||5 Ago 2008||18 Dic 2008||Aries Associates, Inc.||Scanning spectrophotometer for high throughput fluorescence detection|
|US20080309934 *||6 Ago 2008||18 Dic 2008||Aries Associates, Inc.||Scanning spectrophotometer for high throughput fluorescence detection|
|US20090157054 *||18 Dic 2007||18 Jun 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||Treatment indications informed by a priori implant information|
|US20090157055 *||20 Dic 2007||18 Jun 2009||Searete Llc, A Lomited Liability Corporation Of The State Of Delaware||Treatment indications informed by a priori implant information|
|US20090215754 *||17 Oct 2006||27 Ago 2009||Hochman Daryl W||Methods and compositions for the treatment of neuropsychiatric and addictive disorders|
|US20090258844 *||15 Abr 2009||15 Oct 2009||Neurotherapeutics Pharma, Inc.||Compositions and methods for the treatment of disorders of the central and peripheral nervous systems|
|US20090281412 *||30 Abr 2009||12 Nov 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||System, devices, and methods for detecting occlusions in a biological subject|
|US20090281413 *||30 Abr 2009||12 Nov 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||Systems, devices, and methods for detecting occlusions in a biological subject|
|US20090284378 *||13 May 2008||19 Nov 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||Circulatory monitoring systems and methods|
|US20090287076 *||30 Abr 2009||19 Nov 2009||Boyden Edward S||System, devices, and methods for detecting occlusions in a biological subject|
|US20090287093 *||15 May 2008||19 Nov 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||Circulatory monitoring systems and methods|
|US20090287110 *||15 May 2008||19 Nov 2009||Searete Llc||Circulatory monitoring systems and methods|
|US20090287137 *||15 Abr 2009||19 Nov 2009||Boston Scientific Corporation||Mucosal ablation|
|US20090292195 *||30 Abr 2009||26 Nov 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||System, devices, and methods for detecting occlusions in a biological subject including spectral learning|
|US20090292213 *||21 May 2008||26 Nov 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||Circulatory monitoring systems and methods|
|US20090292222 *||21 May 2008||26 Nov 2009||Searete Llc||Circulatory monitoring systems and methods|
|US20090318802 *||30 Abr 2009||24 Dic 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||System, devices, and methods for detecting occlusions in a biological subject|
|US20100036209 *||7 Ago 2008||11 Feb 2010||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||Circulatory monitoring systems and methods|
|US20100036268 *||7 Ago 2008||11 Feb 2010||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||Circulatory monitoring systems and methods|
|US20100036269 *||7 Ago 2008||11 Feb 2010||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||Circulatory monitoring systems and methods|
|US20100249607 *||28 Sep 2009||30 Sep 2010||Massachusetts Institute Of Technology||Quantitative spectroscopic imaging|
|US20110110567 *||4 Ago 2010||12 May 2011||Chunsheng Jiang||Methods and Apparatus for Visually Enhancing Images|
|US20120179010 *||5 Ene 2012||12 Jul 2012||Maynard John D||Determination of a Measure of a Glycation End-Product or Disease State Using Tissue Fluorescence of Various Sites|
|US20140303504 *||29 Oct 2012||9 Oct 2014||Massachusetts Eye & Ear Infirmary||Tissue and cellular imaging|
|US20160313244 *||18 Abr 2016||27 Oct 2016||Panasonic Intellectual Property Management Co., Ltd.||Optical sensing apparatus provided with light source and light detector|
|EP1877945A2 *||25 Abr 2006||16 Ene 2008||Horiba Jobin Yvon Inc||Method for classification of carbon nanotues and other materials|
|EP1877945A4 *||25 Abr 2006||21 Nov 2012||Horiba Jobin Yvon Inc||Method for classification of carbon nanotues and other materials|
|WO1997006724A1 *||14 Ago 1996||27 Feb 1997||Centre National De La Recherche Scientifique (Cnrs)||Endoscopic imaging for the detection of cancer lesions|
|WO1999013764A1 *||11 Sep 1998||25 Mar 1999||Communaute Europeenne||Detecting and mapping inflamed zones in a living tissue|
|WO2001008552A1 *||2 Ago 2000||8 Feb 2001||Biophysica, Llc||Spectroscopic systems and methods for detecting tissue properties|
|WO2002024048A3 *||25 Sep 2001||18 Jul 2002||Avraham Mayevsky||Apparatus and method for monitoring tissue vitality parameters|
|Clasificación de EE.UU.||600/476, 600/477, 600/478|
|Clasificación cooperativa||G01J3/4406, G01N2021/6484, G01N2021/6417, A61B5/0059, G01N21/6456, G01N2021/6419|
|Clasificación europea||A61B5/00P, G01J3/44B, G01N21/64P4|
|8 Feb 1993||AS||Assignment|
Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:RICHARDS-KORTUM, REBECCA;REEL/FRAME:006423/0327
Effective date: 19930202
Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:RAVA, RICHARD;REEL/FRAME:006419/0087
Effective date: 19930104
|8 Abr 1993||AS||Assignment|
Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BARAGA, JOSEPH;REEL/FRAME:006490/0491
Effective date: 19930323
|17 Sep 1996||FPAY||Fee payment|
Year of fee payment: 4
|7 Nov 2000||REMI||Maintenance fee reminder mailed|
|29 Mar 2001||SULP||Surcharge for late payment|
Year of fee payment: 7
|29 Mar 2001||FPAY||Fee payment|
Year of fee payment: 8
|15 Sep 2004||FPAY||Fee payment|
Year of fee payment: 12